Zachary Avigan MD; IMS 2026: Predicting Multiple Myeloma Cure: Ultra-Low-Risk Patients Who Have Favorable Outcomes and Can Stop Therapy

Zachary Avigan MD; IMS 2026: Predicting Multiple Myeloma Cure: Ultra-Low-Risk Patients Who Have Favorable Outcomes and Can Stop Therapy

Zachary Avigan MD, Assistant Professor of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York City, USA
International Myeloma Society 2026 Annual Meeting
9:18

GLASGOW, Scotland—Patients who achieved sustained measurable residual disease negativity for more than 24 months had significantly improved survival outcomes and could be categorized as cured. This isthe implication of findings from a retrospective analysis looking at predicting cure in myeloma reported at the International Myeloma Society 2026 Annual Meeting. Sarah Maxwell heard the details from study author Zachary Avigan MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Icahn School of Medicine in Mount Sinai Hospital, New York City, USA.

Predicting Multiple Myeloma Cure: Ultra-Low-Risk Patients Who Have Favorable Outcomes and Can Stop Therapy

An Interview with:

Zachary Avigan MD, Assistant Professor of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York City, USA

GLASGOW, Scotland—Patients who achieved sustained measurable residual disease negativity for more than 24 months had significantly improved survival outcomes and could be categorized as cured. This isthe implication of findings from a retrospective analysis looking at predicting cure in myeloma reported at the International Myeloma Society 2026 Annual Meeting.

Sarah Maxwell heard the details from study author Zachary Avigan MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Icahn School of Medicine in Mount Sinai Hospital, New York City, USA.

AUDIO JOURNAL OF ONCOLOGY; Zachary Avigan MD

IN: “Welcome to the Audio Journal of Oncology…”

OUT: “…from myself Sarah Maxwell, it’s goodbye for now” 9:18 secs

DURATION:

SOURCE:

International Myeloma Society 2026 Annual Meeting

Zachary Avigan MD

Abstract:

Predicting Cure in Myeloma: Sustained MRD dynamics, genomic risk, and ISS define ultra-low-risk subgroup with favorable outcomes after stopping therapy Author: Zachary Avigan

Link to abstract:

https://www.ovid.com/journals/clml/abstract/10.1016/s2152-2650(26)03357-4~oa-56-predicting-cure-in-myeloma-sustained-mrd-dynamics?redirectionsource=fulltextview

Hash tags:

#AJO

#Interview

#ZacharyAviganMD

#Hematology

#Oncology

#Cancer

#Myeloma

#MultipleMyeloma

#InternationalMyelomaSociety

#InternationalMyelomaSociety2026

#23rdInternationalMyelomaSocietyMeeting

#IMS2026

#AudioJournalOfOncology

#ZacharyAvigan

#InternationalMyelomaSocietyAnnualMeeting

260929 Zachary Avigan MD, IMS 2026 A J Oncology Text